First-In-Human Phase 1 Trial of the Safety and Immunogenicity of a Recombinant Adenovirus Serotype 5 HVR48 (rAd5HVR48) HIV-1 Vaccine
Retrovirology - United Kingdom
doi 10.1186/1742-4690-9-s2-o52
Full Text
Open PDFAbstract
Available in full text
Date
September 1, 2012
Authors
Publisher
Springer Science and Business Media LLC